Acta Pharmaceutica Sinica B 2025;15(11):6087−6088

Chinese Pharmaceutical Association
Institute of Materia Medica, Chinese Academy of Medical Sciences

Acta Pharmaceutica Sinica B

www.elsevier.com/locate/apsb
www.sciencedirect.com

COMMENTARY

AT-17 redefines local anesthetics by targeting mitochondrial apoptosis

KEY WORDS

Oral local anesthetics;
Articaine;
Mitochondria;
Apoptosis

The development of novel local anesthetics has long been mired in a cycle of incremental optimization, primarily focusing on sodium channel kinetics and pharmacokinetic refinement. The work by Hao et al.[1], featured in this issue, constitutes a genuine paradigm shift that fundamentally redefines the potential of local anesthetics. Their compound, **AT-17**, transcends the conventional category of sodium channel blockers; it represents a multifunctional therapeutic agent that directly addresses the core pathophysiology responsible for anesthetic failure under inflammatory conditions.

1. From symptom to source: A mechanistic breakthrough

For decades, the "acidic environment" hypothesis has dominated explanations for local anesthetic failure in inflammation[2]. This study elegantly advances beyond this limited perspective to uncover a deeper biological truth: inflammation-induced mitochondrial dysfunction and neuronal apoptosis are critical determinants of anesthetic efficacy. The compelling demonstration that **AT-17**'s analgesic effects can be reversed by a mitochondrial apoptosis activator (ABT-737) provides robust evidence establishing this novel mechanistic connection.

Perhaps most striking is the revelation of sodium's dual role in **AT-17**'s mechanism. Sodium serves not only as the primary target for anesthetic action[3] but also functions as a key second messenger mediating anti-apoptotic effects through the Na^+/NCLX/ETC/mtROS axis. This elegant research bridges classical pharmacodynamic targets (Na_V channels)[4] with sophisticated intracellular signaling pathways that maintain cellular integrity. The discovery that **AT-17** reduces mitochondrial sodium loading—thereby restoring Complex I and III activity while reducing mtROS production—establishes a coherent mechanistic narrative spanning from molecular targets to cellular outcomes.

2. Therapeutic implications and clinical potential

AT-17 demonstrates substantial translational promise. The authors document superior efficacy across multiple clinically relevant models, ranging from chemical-induced pain (formalin and carrageenan) to clinically analogous oral procedures (extraction and pulpitis). The compound's prolonged duration of action in inflammatory settings, combined with an improved therapeutic index, suggests significant potential for enhancing patient comfort during inflammatory dental procedures where conventional anesthetics often prove inadequate.

From a safety standpoint, the selective inhibition profile—showing potent effects on $Na_V1.7/1.8$ with minimal activity on cardiac $Na_V1.5$[5]—is particularly encouraging. This selectivity, augmented by activation of endogenous protective pathways (NRF2), positions **AT-17** as a potentially safer alternative to existing agents, especially for patients with cardiovascular comorbidities.

3. Broader scientific impact and future directions

This research inaugurates several promising investigative pathways:

Beyond dental applications: The underlying mechanism suggests potential utility in other inflammatory pain conditions, including arthritic and neuroinflammatory disorders.

Peer review under the responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.

https://doi.org/10.1016/j.apsb.2025.10.013

Mitochondria as an analytical target: This work establishes mitochondrial function as a legitimate target for future analgesic development, moving beyond exclusive focus on neuronal membrane targets.

AI-driven drug discovery validation: **AT-17**'s success, originating from the DeepSA generative framework[1], provides compelling validation for AI-augmented drug discovery in addressing complex therapeutic challenges.

4. A minor limitation and a significant strength

Although the study offers comprehensive exploration of the mitochondrial apoptosis pathway, the relative contributions of $Na_V1.7$ *versus* $Na_V1.8$ inhibition to the overall analgesic effect across different inflammatory contexts merit further investigation. Nevertheless, this consideration does not diminish the central breakthrough: the demonstration that enhanced mitochondrial function directly improves anesthetic efficacy—a conceptual advancement that will undoubtedly influence the field for years to come.

5. Conclusion

Hao and colleagues have achieved more than developing a new pharmaceutical agent; they have fundamentally reshaped our conceptual framework for local anesthesia. In an era of targeted therapies, **AT-17** emerges as a rationally designed, multifunctional compound that addresses the root cause of anesthetic failure in inflammation. This research successfully integrates ion channel pharmacology with cellular biology, offering a sophisticated solution to a persistent clinical challenge. It represents a pivotal advancement, promising not only improved pain management for patients but also a new trajectory for innovative drug discovery in anesthesiology.

References

1. Hao YH, Wang HF, Liu XG, Gai WR, Hu SL, Liu WC, et al. Deep simulated annealing for the discovery of novel dental anesthetics with local anesthesia and anti-inflammatory properties. *Acta Pharm Sin B* 2024;**14**:3086−109.
2. Ueno T, Tsuchiya H, Mizogami M, Takakura K, et al. Local anesthetic failure associated with inflammation: verification of the acidosis mechanism and the hypothetic participation of inflammatory peroxynitrite. *J Inflamm Res* 2008;**1**:41−8.
3. Yang Li, Gong HP. Theoretical and simulation studies on voltage-gated sodium channels. *Protein Cell* 2015;**6**:413−22.
4. Cardoso FC, Lewis RJ. Sodium channels and pain: from toxins to therapies. *Br J Pharmacol* 2018;**175**:2138−57.
5. Jiang DH, Shi H, Tonggu L, Gamal El-Din TM, Lenaeus MJ, Zhao Y, et al. Structure of the cardiac sodium channel. *Cell* 2020;**180**:122−134. e10.

Xiaoyuan Chen
Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119074, Singapore
Department of Chemical and Biomolecular Engineering, College of Design and Engineering, National University of Singapore, Singapore 117575, Singapore
Department of Biomedical Engineering, College of Design and Engineering, National University of Singapore, Singapore 117575, Singapore
Department of Pharmacy and Pharmaceutical Sciences, Faculty of Science, National University of Singapore, Singapore 117544, Singapore
Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117599, Singapore
Nanomedicine Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore
Theranostics Center of Excellence (TCE), Yong Loo Lin School of Medicine, National University of Singapore, Singapore 138667, Singapore
*Institute of Molecular and Cell Biology, Agency for Science, Technology, and Research (A*STAR), Singapore 138673, Singapore*
E-mail address: chen.shawn@nus.edu.sg